Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luciano Mutti

Showing results (31-40 of 124) with videos related to

Pageof 13
Sort By:
Frontiers in Molecular Biosciences|June 30, 2022
Identification and Validation of lncRNA-AC087588.2 in Lung Adenocarcinoma: A Novel Prognostic and Diagnostic IndicatorXiulin Jiang, Xi Chen, Jishu Guo, et al.
Journal of Cellular and Molecular Medicine|May 9, 2012
Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2+ channel openingElia Ranzato, Simona Martinotti, Valeria Magnelli, et al.
Plos Computational Biology|November 7, 2017
Insight into glucocorticoid receptor signalling through interactome model analysisEmyr Bakker, Kun Tian, Luciano Mutti, et al.
Genes & Cancer|February 14, 2017
Switching off malignant mesothelioma: exploiting the hypoxic microenvironmentNoushin Nabavi, Kevin L Bennewith, Andrew Churg, et al.
International Journal of Molecular Sciences|July 29, 2020
HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across ItalyPierpaolo Correale, Luciano Mutti, Francesca Pentimalli, et al.
International Journal of Molecular Sciences|January 24, 2019
<i>BAP1</i> Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine TreatmentAlice Guazzelli, Parisa Meysami, Emyr Bakker, et al.
Expert Opinion on Investigational Drugs|July 3, 2019
What can independent research for mesothelioma achieve to treat this orphan disease?Alice Guazzelli, Parisa Meysami, Emyr Bakker, et al.
Journal of Cellular Physiology|September 5, 2002
Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell linesSalvatore Toma, Lucia Colucci, Linda Scarabelli, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patientsCamillo Porta, Matteo Zimatore, Lucia Bonomi, et al.
Cancer Research|June 17, 2005
SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposurePaola Cacciotti, Dario Barbone, Camillo Porta, et al.
Pageof 13

Showing results (31-40 of 124) with videos related to

Sort By:
Pageof 13
Frontiers in Molecular Biosciences|June 30, 2022
Identification and Validation of lncRNA-AC087588.2 in Lung Adenocarcinoma: A Novel Prognostic and Diagnostic IndicatorXiulin Jiang, Xi Chen, Jishu Guo, et al.
Journal of Cellular and Molecular Medicine|May 9, 2012
Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2+ channel openingElia Ranzato, Simona Martinotti, Valeria Magnelli, et al.
Plos Computational Biology|November 7, 2017
Insight into glucocorticoid receptor signalling through interactome model analysisEmyr Bakker, Kun Tian, Luciano Mutti, et al.
Genes & Cancer|February 14, 2017
Switching off malignant mesothelioma: exploiting the hypoxic microenvironmentNoushin Nabavi, Kevin L Bennewith, Andrew Churg, et al.
International Journal of Molecular Sciences|July 29, 2020
HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across ItalyPierpaolo Correale, Luciano Mutti, Francesca Pentimalli, et al.
International Journal of Molecular Sciences|January 24, 2019
<i>BAP1</i> Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine TreatmentAlice Guazzelli, Parisa Meysami, Emyr Bakker, et al.
Expert Opinion on Investigational Drugs|July 3, 2019
What can independent research for mesothelioma achieve to treat this orphan disease?Alice Guazzelli, Parisa Meysami, Emyr Bakker, et al.
Journal of Cellular Physiology|September 5, 2002
Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell linesSalvatore Toma, Lucia Colucci, Linda Scarabelli, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patientsCamillo Porta, Matteo Zimatore, Lucia Bonomi, et al.
Cancer Research|June 17, 2005
SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposurePaola Cacciotti, Dario Barbone, Camillo Porta, et al.
Pageof 13